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This article presents the ERS Early Career Member Award winner 2021 (@agbasteiro), and provides 
a brief description of the @EuroRespSoc Lung Science Conference 2022 and the Respiratory Channel 
https://bit.ly/2XTylbK
In this article, we present an interview conducted 
with the winner of the European Respiratory 
Society (ERS) Early Career Member Award 2021, 
Alberto García-Basteiro, where he discussed his 
work and visions for the future. We also provide 
an overview of the ERS Lung Science Conference 
2022, which will take place in Estoril (Portugal), 
with a brief description of the early career member 
(ECM) session. Finally, we discuss the most recent 
digital resource from ERS available to the respiratory 
community, the ERS Respiratory Channel.
Interview with the ERS 
ECM Award winner, 
Alberto García-Basteiro
The ECM Award is intended to honour a promising 
member of the ERS, aged 40 years old or younger, 
with strong potential for future contributions within 
the respiratory field. This year, the ECM Award 
winner was Alberto García-Basteiro (figure 1). Dr 
García-Basteiro is 39 years old and was born in 
Spain. Currently, he works at the Barcelona Institute 
for Global Health (ISGlobal, Barcelona, Spain) as 
an Associate Research Professor and he is the 
Coordinator of the Tuberculosis and HIV area in the 
Manhiça Health Research Centre (CISM), in Maputo 
(Mozambique). He has been an ERS member since 
2014 and he is currently the Chair of Group 10.02 of 
Assembly 10 (Respiratory infections) on tuberculosis 
and nontuberculous mycobacteria (2020–2023). 
As a recognition of his remarkable contribution to 
respiratory medicine, Dr García-Basteiro provided 
the Mina Gaga Lecture during the dedicated ECM 
session of the ERS International Congress 2021 
entitled Keys to success in science, organised by the 
Early Career Member Committee (ECMC), where 
he presented his main career achievements 
and scientific work. Dr García-Basteiro was also 
interviewed by two ECMs from Assembly 10 
(J.C. Costa and P. Mitchelmore), in a virtual format, 
to share his experience as a successful ECM and to 
provide new insights for the future. The interview 
is presented below.
How did you become interested 
in tuberculosis, since you are 
from Spain, a low-incidence 
country, and what led you to 
Mozambique in particular?
I have been very interested in research since I was in 
medical school. I was involved in the International 
Federation of Medical Students’ Associations 
(IFMSA), and the contact with colleagues abroad and 
the exchange of experiences with them make me 
wish to pursue a career in global health. I realised 
at that time that I would like to put my efforts into 
coming up with solutions for diseases that are 
responsible for a huge burden in places that are 
already struggling with a lack of resources. During 
my Public Health residence, I worked in the fields 
of dengue and malaria. TB research appeared to 
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me as an opportunity, I was invited by the former 
director of the Barcelona Institute for Global Health 
(ISGlobal), Prof. Pedro Alonso, to embrace a huge 
challenge: to do field research at the Centro de 
Investigação de Saúde de Manhiça (CISM, Manhiça 
Health Research Centre) in Mozambique, a 
longstanding partner of ISGlobal. They were looking 
for an epidemiologist to move there for 3–4 years in 
order to answer key research questions about TB in 
a high-burden country like Mozambique. I had no 
doubts and I decided to take the challenge. That is 
how TB and Mozambique became linked to my life 
and to my career.
Should we be optimistic or 
pessimistic about the global 
response and management 
of TB in the coming years?
Looking at what has been done for COVID-19 in 
the past year and a half, I am quite frustrated 
that nothing of this magnitude has ever been 
done in TB research or control. This is particularly 
frustrating given the known burden and death 
toll associated with TB. We have shown that we 
are capable of doing great things when we are 
threatened. However, when a disease is mostly 
affecting poor countries, we have not managed 
to mobilise the needed resources to cope with 
these scourges of humankind that have been 
ongoing for centuries. We could have done it 
and the question for the coming years is: are we 
going to learn something from COVID-19 to apply 
to other diseases? I am sceptical, to be honest. 
I think that, when the pandemic is over, we will 
likely go back to “business as usual” if high income 
countries are not severely affected by TB. I think 
rich countries will focus on other health issues 
and we will not take this amazing opportunity and 
example of global health response to fight other 
big diseases that are causing millions of deaths. 
I really hope that the international community 
supports new technologies (i.e. mRNA vaccines) 
arising from COVID-19 research in the field of 
TB research.
In 2019, it was estimated that TB cost 1.4 million 
lives, and potentially more in 2020 given the lack 
of access to and disruptions to health services in 
many high TB burden countries. I am pessimistic 
about the idea of high-income countries focusing 
on changing this. We are seeing this attitude already 
around COVID-19. In Mozambique today, only 
1.5% of the population has been vaccinated with 
two doses of the vaccine. We could have taken a 
more equitable response to the pandemic. Instead, 
we have made sure that the rich countries get 
vaccinated, and as for the poor countries – let’s 
see what happens.
How do you think that medical 
societies, such as the ERS, could 
help fighting respiratory diseases 
in third world countries?
I believe that scientific societies play an important 
role for facilitating scientific discussion and as 
organisations that allow researchers to create 
and to work with international peers to find 
collaborative solutions for global health problems. 
They are also important entities that can train 
health professionals in the different fields. The 
ERS to me is an inspiring scientific society. TB 
is not a huge health problem in most parts of 
Europe, although drug-resistant TB is still a topic 
of concern, particularly in the eastern Europe. I have 
found in the ERS a space for debate, for training and 
for ongoing TB research; a place that is inclusive, 
even for researchers outside Europe.
Who and what have been your 
inspirations and motivations 
for your research career?
I would like to be part of a solution to health 
problems that affect millions of people in poor 
countries. Fighting diseases is always a challenge 
but doing so in under-resourced settings is a double 
challenge. Many of these diseases (e.g. malaria, HIV 
and other neglected tropical diseases) are poverty-
related diseases. Dedicating my time and efforts to 
this task makes all the sense to me and seems the 
right thing to do.
Figure 1 Alberto García-Basteiro, the ERS Early Career 
Member Award winner in 2021.
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I have several professional inspirations. Leaving 
aside those who no longer are with us, one of them, 
of course, is Dr. Pedro Alonso, who was the one who 
offered me the possibility to be part of this ISGlobal 
and CISM family. His extraordinary scientific and 
public health career has translated into public policy 
and has contributed to trying to find solutions in the 
field of malaria. In the field of TB, there are many 
researchers that I really admire. Prof. Frank Cobelens 
was my PhD director at the Amsterdam Institute for 
Global Health and Development. He is an outstanding 
epidemiologist, and every time I talk to him new ideas 
and interesting discussions come up. I also have great 
admiration for Prof. Katherine Fielding and Prof Paul 
Fine, at the London School of Hygiene and Tropical 
Medicine, and Prof. Gavin Churchyard at the Aurum 
Institute in Johannesburg, to name just a few. They 
are amazing researchers and a source of constant 
motivation for me. These are some of the important 
researchers that I try to learn from.
What has been your biggest 
frustration as a researcher?
My biggest frustration or worry as a researcher 
is to receive funding for research projects. We 
apply and fail several times to get one grant. 
There is no wide public support for scientific 
research in Spain, as in other countries. This 
issue relates directly to the personal stability 
of the researchers and may impact careers and 
projects. The scarcity of the grants increases the 
pressure on researchers, as we need to be good, 
very good, constantly, to be financed. We need to 
be focused every time but at the end of the day 
our own personal instability can affect our work 
and peace of mind.
What impact has COVID-19 had on 
your research?
COVID-19 has affected every TB project that I 
know of. In Mozambique, we had to stop some 
studies earlier than expected and others have not 
started yet. Importing reagents and equipment 
has become more and more complicated during 
COVID-19 times. It has also been a cause of an 
ethical dilemma. I was in Spain when COVID-19 
arrived, and I was shocked about the situation with 
lockdowns and thousands of deaths being reported. 
Our Institution (ISGlobal) asked us to contribute 
to the research needs of COVID-19. There were 
so many in March 2020, from basic disease 
epidemiology to diagnostic tests, treatments, etc. 
At the beginning, it was hard to get good estimates 
of what was going on with the burden of the disease 
and infection. Everything had to be described, so 
we tried to contribute to that.
The ethical dilemma came from dedicating 
a lot of time, that was supposed to be put into 
one disease (TB) that is killing a lot of people, 
to another disease (COVID-19). Furthermore, 
this other disease has less impact in countries 
with a high burden of TB because of the age 
distribution of the population. For example, in 
Mozambique, 50% of the population is under 
16 years old. People are getting infected but the 
number of people that are very ill or die are a 
lower proportion of the population compared 
with European countries. Neglecting an already 
neglected disease, such as TB, was a big problem 
for me. Consequently, I returned to dedicating all 
my energy to TB research as I believe this is the 
right thing to do. After the COVID-19 pandemic, 
the high TB burden countries are going to face 
a huge problem. The Stop-TB Partnership has 
estimated that there are going to be around 
1 400 000 additional deaths in the next 5 years 
because of the disruption of the pandemic.
What are the lessons to be 
learnt from the pandemic?
There are so many lessons to be learnt from 
COVID-19. One of the conclusions of the report 
of the independent panel that evaluated the 
international response to COVID-19 was that, if 
we had followed some of the recommendations 
from previous outbreaks and pandemics (such as 
Zika virus and Ebola), then we would not be in this 
horrible position. So, preparedness, prevention, and 
learning from the past is crucial. For me, there is one 
particular lesson which I wish we pay more attention 
to in the future and that is the global response. We 
are seeing new viral variants being spread and 
very high transmission rates in places where the 
vaccination coverage is low. This is a great threat for 
the generation of new variants to go back to high 
income countries and perhaps being less susceptible 
to vaccines. If we do not pay attention and think of 
a global response to COVID 19, the situation can be 
perpetuated. Vaccination coverage is 1.5% for sub-
Saharan Africa with two doses (as of mid-July 2021).
In Europe, we may have made some progress 
in the response. If the COVID-19 pandemic 
happened 20–30 years ago, we may have seen 
Germany, the UK and Russia get vaccinated 
before other poorer European countries. That 
would now be seen as unacceptable and non-
equitable within Europe. However, our horizon 
as a species should not be Europe but the entire 
planet. This will require significant political will in 
the international affairs arena, but I think it should 
be possible and I hope we are learning now that 
this is the right response.
What do you imagine yourself to 
invent, create or achieve as your 
masterpiece in your career?
I wish I can contribute to the development 
of new tools, transformative tools, that can 
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directly impact the populations’ health, such as 
vaccines. The available TB vaccine, the BCG, is 
already 100 years old and, as we know, it is not 
very effective in the prevention of pulmonary 
TB in adults. If I could contribute with my work 
to the development of an effective tool such 
as a new vaccine, I will be more than satisfied 
at a professional level. Additionally, I want to 
contribute to the development of the local health 
and research structures as well as to the training 
of local fellows in Africa.
Where do you see yourself 
5 years from now?
I see myself continuing to research TB because, 
sadly, we still have a lot of work to do! I will be 
looking to implement more projects coming from 
my own ideas. That will mean that I am advancing 
professionally and scientifically. I hope that, in 
5 years, I can still be involved in teaching activities, 
which is something I also enjoy very much.
What does this award and 
the ERS mean to you?
This award is a great source of motivation and a 
boost of energy. Overall, it probably means that 
our team is doing some good work and that we are 
doing research in the right direction. It is always 
important to be recognised, especially outside of 
your own institution. To be given an award from 
the biggest respiratory scientific organisation in 
the world, the ERS, is also a responsibility for the 
future and a reason for humbleness, motivation 
and focus.
What advice would you give 
to someone entering the world 
of respiratory research?
Who am I to give advice? I have learnt that 
networking and collaborations are very important. 
You have to be exposed to the work that others 
are doing. Anyone that wants to enter the field of 
respiratory research needs to team up, join societies 
and organisations where they can meet researchers, 
doctors and healthcare professionals from other 
countries. We have a lot to learn from each other, 
such as how others work in their environments, 
their different techniques and how they approach 
research ideas. It can be very eye-opening to 
realise that the same solutions might not apply 
everywhere. In addition, it is such an enriching 
experience to work with international colleagues.
I think it is very important that research methods 
are taught in depth at medical schools, but this 
is not always the case. We should involve young 
residents and even undergraduates to be part of 
research projects early on in their careers. The more 
you see research, the more likely you want to be 
part of it at a later stage.
You have been actively involved 
in the ERS. Do you think that 
this involvement had an impact 
on your career? And, if so, how?
I have been involved in the ERS since 2013. My 
involvement started as soon as I realised that my 
field of work was going to be a major (mostly) 
respiratory disease such as TB. This involvement 
allowed me to meet amazing colleagues, to 
integrate research networks and to be part of a 
new professional family. This cooperative work 
allows us to develop research projects, apply 
for research grants and be involved in teaching 
activities. Despite the low incidence of TB in 
many parts of Europe, it has not gone away. 
There are, for example, around 4000 to 5000 
cases per year only in Spain. For this reason, we 
must be aware and vigilant in Europe as TB is still 
an important differential diagnosis that must be 
constantly considered in almost any specialty. 
Overall, being involved with the ERS gave me 
access to postgraduate training, some of them 
were satellites to the ERS Congress, the TBNet 
network and the ECM events.
What would you say to ECMs 
who are currently in a similar 
position as you were 5 years ago?
I would say to be cheeky! Try to be involved in some 
of the activities of the ERS. It will bring you more 
than we bring to the Society, so it is a win–win 
scheme. I would definitely tell them to try to set a 
plan for their professional development. Try to take 
advantage of the opportunities of the ERS, especially 
of the networking opportunities at the scientific 
activities. This will make you a better professional 
and a better researcher.
Preview of the ERS Lung 
Science Conference 2022
After a fully online event in 2021, the 20th ERS 
Lung Science Conference (LSC) will take place 
in Estoril (Portugal) on 10–13 March 2022. The 
LSC is at the forefront of basic and translational 
respiratory science and provides a unique 
opportunity for early career and renowned 
respiratory professionals to network with peers 
from across the globe and share cutting-edge 
findings in the field of experimental lung research. 
The 20th LSC will be centred around the theme 
of Mucosal immunology of the lung: balancing 
protective immunity and chronic inflammation and 
the conference programme has been developed 
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by an expert committee consisting of Reinoud 
Gosens (ERS Conferences and Seminar Director), 
Martijn Nawijn, Florence Schleich and Önder 
Yildirim. The sessions will focus on the important 
topics of the lung cell atlas in health and disease, 
tissue resident and recruited immunity, trained 
immunity, mucosal immunity in the lung and 
infections and, lastly, cytokine targeted therapies 
and personalised medicine in respiratory 
diseases (https://www.ersnet.org/events/
lung-science-conference-2022/programme/).
During the LSC, the ECMC organises a dedicated 
session for ERS ECMs. The topic of this year’s 
session is Tools for career development and will 
include presentations about “Effective teaching 
and mentoring”; “How to collaborate successfully”, 
from both an industry and academia perspective; 
“A career in scientific editing”; and a discussion 
on “Transferable skills”. This session will provide 
insights into topics important for the development 
of early career professionals, but not always directly 
addressed within their training. Following the 
presentations, a panel discussion and networking 
event will take place during which the audience, 
and specifically all ECMs, can pose questions they 
may have and share their experiences.
The LSC provides unique opportunities for early 
career professionals to present their research 
as a thematic poster presentation or an oral 
presentation. The format of the presentation will 
be selected based on the quality of the abstracts 
and the five highest ranked abstracts submitted by 
ECMs will be presented in the Young Investigator 
Session and are thus nominated for the prestigious 
William MacNee award. Moreover, the best oral 
presentation will be awarded with the Geoffrey 
Laurent award and all poster presenters are eligible 
for a distinguished poster prize. Selected abstract 
authors who have applied for and received a bursary 
will be assigned a mentor with whom they can 
discuss various aspects of their research and career 
development in respiratory medicine during a 
dedicated mentor lunch.
Overall, the LSC 2022 provides an exciting 
scientific programme and an excellent opportunity 
for ECMs to interact with and establish networks 
with current and future leaders in the field of 
respiratory science. Moreover, there will be many 
opportunities to discuss your future involvement 
in ERS activities with ERS officers and ECM 
representatives. We look forward to welcoming you 
in Estoril for the 20th LSC in March 2022!
ERS Respiratory Channel
The ERS Respiratory Channel (https://www.
ersnet.org/ers-respiratory-channel/) is a new 
online resource which was designed to respond 
to the growing needs of the respiratory community 
for increased and accessible digital content. The 
COVID-19 pandemic further increased this need as 
it forced a shift to online activities and events. The 
channel was launched on 1 February 2021 with a 
free COVID-19 webinar, Understanding new vaccines 
for SARS-CoV-2 and their regulation, chaired by the 
ERS President Anita Simonds (London, UK) and 
Tobias Welte (Hannover, Germany).
The purpose of the ERS Respiratory Channel is to 
provide professionals and researchers working in the 
respiratory field with a single online location where 
the latest digital content from ERS/European Lung 
Foundation (ELF) can be easily accessed, including 
online activities and events already produced/
delivered by ERS and ELF, as well as new content 
made specifically for the channel. There is also 
specific content for respiratory patients which is 
tagged as “patient focused”.
In terms of content, the channel delivers:
	● Live events and activities. Some of the activities 
are free and others are paid. These activities 
include educational courses, webinars, 
conferences, patient focused events, and panel 
discussions. Anyone visiting the channel can 
see which live online events are taking place 
that week and over the next few weeks. They 
can get further information and register for the 
events and, on the day, they can access their 
chosen events from the channel landing page.
	● A wide range of content which is free and 
immediately accessible. This includes 
recordings of some live events such as the ERS 
Vision Live panel discussions, ERS podcasts, 
patient perspective videos, short educational 
videos, etc.
	● Dynamic content. The content is regularly 
updated and ever changing based on what is 
current in the respiratory field. It is also capped 
so that it isn’t overloaded, this means that the 
channel is very easy to navigate, and it is easy to 
see the full content in a short amount of time. 
The idea is that people who visit it regularly will 
get the most out of it.
	● Content from the ERS industry partners. There is 
a separate content page on the channel which 
features digital content from ERS industry 
partners (https://www.ersnet.org/industry-
channel/). It is important to note that ERS does 
not collaborate on this content, nor is any of this 
content produced or endorsed by ERS.
The ERS Respiratory Channel is a dynamic 
platform, which means that the platform can 
develop over time according to the need of the 
respiratory community. Changes may include 
introducing new features and/or developing the 
format as it moves forward. Follow the channel 
regularly to find out what’s new!
The ECMs have been actively involved in various 
activities and events on the ERS Respiratory 
Channel. If you are interested in participating in 
these activities, please contact your Assembly 
officers or your ECM representative to find out how 
you can collaborate in future activities.
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Final remarks
This article presented the ERS ECM Awardee 2021 
and provided information on some of the ERS 
activities available to the respiratory community. 
Keep up to date with the latest events and activities by 
visiting the ERS Respiratory Channel and by following 
us on Twitter (@EuroRespSoc and @EarlyCareerERS) 
and/or Facebook (@EuropeanRespiratorySociety, 
ERS Early Career Members group).
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